Please login to the form below

Not currently logged in
Email:
Password:

Merck buys cancer-killing virus firm Viralytics for $394m

It will acquire the Australian biotech’s lead cancer therapy Cavatek in the process

Merck & CoMerck & Co has bolted on another immuno-oncology asset to pair with its flagship checkpoint inhibitor Keytruda in clinical trials.

The pharma group - known as MSD outside the US and Canada - has agreed to buy Australian biotech Viralytics and Cavatek (CVA21), the company’s lead virus-based cancer therapy which is currently in several phase I and II trials. That includes studies testing the combination with Keytruda (pembrolizumab) under the terms of a 2015 agreement between the two companies.

The deal is the latest in a series of deals by the big players in cancer immunotherapy as they try to anticipate which new technologies and combinations will complement the current wave of PD-1 and PD-L1 inhibitors, which are already pulling in billions of dollars in sales but don’t work in a sizeable proportion of patients.

Viralytics’ approach is to use a virus called coxsackievirus Type A21 - which seems to preferentially infect and kill cancer cells - to fight tumours.

Roy Baynes, Merck’s chief medical officer, said: “Viralytics’s approach of engaging the innate immune system to target and kill cancer cells complements our immuno-oncology strategy, which is focused on the rapid advancement of innovative monotherapy approaches and synergistic combinations to help the broadest range of cancer patients.”

Trials of Cavatek with Keytruda are ongoing in melanoma, prostate, lung and bladder cancers, and the two companies have already reported phase Ib data showing that the duo achieved a 100% disease control rate in 10 melanoma patients, reducing tumour size in seven and stabilising disease in the remaining three.

Merck has agreed to pay A$502m ($394m) for Sydney-based Viralytics, which will become a wholly-owned Merck subsidiary if the deal goes through. It is however conditional on no better offer emerging from a counter-bidder.

One potentially interested party could be Bristol-Myers Squibb, which makes rival PD-1 inhibitor Opdivo (nivolumab) that has also been tested alongside Cavatek in early-stage trials with impressive results. BMS has been active itself in immuno-oncology M&A however, having just agreed a whopping $3.6bn deal to claim rights to Nektar’s CD122-biased agonist NKTR-214.

Analysts have suggested that another party is however unlikely to come forward at this stage, given the longstanding relationship between Merck and Viralytics and the fact that the boards of both companies are fully behind the takeover.

Article by
Phil Taylor

22nd February 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....